Research programme: small molecule therapeutics - University of Illinois at Chicago/Vanda Pharmaceuticals
Latest Information Update: 28 May 2024
At a glance
- Originator University of Illinois at Chicago; Vanda Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Viral envelope protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections in USA
- 08 Apr 2020 Vanda Pharmaceuticals and University of Illinois at Chicago enter into a R&D agreement for small molecules for COVID-2019 infection
- 08 Apr 2020 Early research in COVID-2019 infections in USA (unspecified route)